Tirzepatide Injection Lots Recalled Nationwide Over Sterility

Apothecary Pharma has recalled 20+ lots of tirzepatide injections nationwide over sterility concerns.

@sharedot

Tirzepatide Injection Lots Recalled Nationwide Over Sterility

By @sharedot · · 6 pages

  • Health
  • Drug Recall
  • Glp 1
  • Tirzepatide

Apothecary Pharma has recalled 20+ lots of tirzepatide injections nationwide over sterility concerns.

What happened: a voluntary nationwide recall

Apothecary Pharma LLC has issued a voluntary recall of certain lots of its tirzepatide injections, the ingredient behind widely used diabetes and weight loss drugs such as Mounjaro and Zepbound. Yahoo reports the recall centers on a "lack of assurance of sterility" in the affected vials.

The impacted product was sold in 18mg/mL and 4mL sterile, multi-dose vials and was available only by prescription. Nearly two dozen lots are included in the recall, spanning lot numbers AP-202622 through AP-202644 with use-by dates running from early October through late November 2026.

The firm did not issue a formal announcement explaining why the recall was issued, according to Yahoo.

Why the risk is rated Class II

The Food and Drug Administration determined that the risks associated with the recalled lots are "remote," and classified the recall as Class II — meaning risks of health consequences are low, but not impossible.

For patients taking tirzepatide, the practical message is reassurance paired with vigilance: the FDA's own framing says serious consequences are unlikely, yet an injection delivered into the body without guaranteed sterility is precisely the kind of defect regulators treat seriously.

NewsBreak reports that patients are being shown how to tell whether their medication is impacted.

How to tell if your vial is affected

According to Yahoo, the recalled lots include AP-202622, AP-202623, AP-202624, AP-202625, AP-202627, AP-202628, AP-202629, AP-202630, AP-202631, AP-202632, AP-202633, AP-202634, AP-202635, AP-202636, AP-202637, AP-202638, AP-202639, AP-202640, AP-202641, AP-202642, and AP-202643, with use-by dates between October 7, 2026 and November 26, 2026.

The affected vials are sterile, multi-dose, prescription-only products in 18mg/mL and 4mL presentations. NewsBreak advises readers to check their medication against the lot list to see whether it is impacted.

Why it matters and what comes next

The FDA's Class II designation suggests regulators see limited danger, and neither source reports any illnesses tied to the recalled lots. The practical next step falls on patients and pharmacies to check lot numbers against the recall list and confirm replacement stock before their next dose.

Sources

  1. yahoo.com › GLP-1 recall: Mounjaro, Zepbound ingredient risk raised to second-highest level
  2. newsbreak.com › GLP-1 recall: Mounjaro, Zepbound ingredient risk raised to second-highest level

More on Health